Beyond melanoma: inhibiting the PD-1/PD-L1 pathway in solid tumors (Q30276874)

14 June 2017

1 reference

title

Beyond melanoma: inhibiting the PD-1/PD-L1 pathway in solid tumors (English)

1 reference

14 June 2017

Patrick Dillon

5

0 references

Craig Slingluff

series ordinal

6

object named as

Craig L Slingluff

1 reference

14 June 2017

3

Paul R Kunk

1 reference

14 June 2017

7

Osama E Rahma

1 reference

14 June 2017

Ryan Gentzler

1

1 reference

PubMed ID

27140411

14 June 2017

Richard Hall

series ordinal

2

1 reference

PubMed ID

27140411

14 June 2017

Elizabeth Gaughan

series ordinal

4

1 reference

14 June 2017

1 May 2016

1 reference

14 June 2017

1 reference

14 June 2017

8

1 reference

14 June 2017

5

1 reference

14 June 2017

583-600

1 reference

Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion

14 June 2017

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2015-0029

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2015-0029

Pembrolizumab versus Ipilimumab in Advanced Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2015-0029

Nivolumab in previously untreated melanoma without BRAF mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2015-0029

21 January 2018

The B7 family revisited

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2015-0029

PD-1:PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells and is overcome by IL-2

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2015-0029

Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2015-0029

Classifying Cancers Based on T-cell Infiltration and PD-L1.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2015-0029

Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2015-0029

Programmed death ligand 2 in cancer-induced immune suppression.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2015-0029

Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2015-0029

Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated head and neck squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2015-0029

Comprehensive molecular characterization of urothelial bladder carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2015-0029

PD-L1 expression in renal cell carcinoma clear cell type is related to unfavorable prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2015-0029

Implications of B7-H1 expression in clear cell carcinoma of the kidney for prognostication and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2015-0029

PD-1 and PD-L1 Expression in Renal Cell Carcinoma with Sarcomatoid Differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2015-0029

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2015-0029

Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2015-0029

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2015-0029

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2015-0029

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2015-0029

Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2015-0029

Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2015-0029

The adaptive immunologic microenvironment in colorectal cancer: a novel perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2015-0029

In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2015-0029

Type, density, and location of immune cells within human colorectal tumors predict clinical outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2015-0029

Cancer classification using the Immunoscore: a worldwide task force

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2015-0029

Towards the introduction of the 'Immunoscore' in the classification of malignant tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2015-0029

Clinical impact of programmed cell death ligand 1 expression in colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2015-0029

Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2015-0029

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2015-0029

Immune infiltrates as predictive markers of survival in pancreatic cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2015-0029

Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2015-0029

The pancreas cancer microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2015-0029

Expression of the costimulatory molecule B7-H3 is associated with prolonged survival in human pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2015-0029

Prognostic impact of tumour-infiltrating immune cells on biliary tract cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2015-0029

Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2015-0029

Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2015-0029

Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2015-0029

Increased PD-1 expression on CD4+ and CD8+ T cells is involved in immune evasion in gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2015-0029

T-cell-mediated tumor immune surveillance and expression of B7 co-inhibitory molecules in cancers of the upper gastrointestinal tract

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2015-0029

Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2015-0029

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2015-0029

Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2015-0029

Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2015-0029

Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2015-0029

Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2015-0029

Tumor-infiltrating lymphocytes, breast cancer subtypes and therapeutic efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2015-0029

Relevance of tumor-infiltrating lymphocytes in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2015-0029

The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2015-0029

Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2015-0029

Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2015-0029

PD-L1 expression in triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2015-0029

Genomic amplification of 9p24.1 targeting JAK2, PD-L1, and PD-L2 is enriched in high-risk triple negative breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2015-0029

Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2015-0029

Pembrolizumab for the treatment of non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2015-0029

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2015-0029

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2015-0029

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2015-0029

Translating Science into Survival: Report on the Inaugural International Cancer Immunotherapy Conference.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2015-0029

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2015-0029

PD-1 blockade induces responses by inhibiting adaptive immune resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2015-0029

Neoantigens in cancer immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2015-0029

Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT-2015-0029

21 January 2018

Identifiers

DOI

10.2217/IMT-2015-0029

1 reference

14 June 2017

1 reference

PubMed ID

27140411